申请人:Clarence-Smith Kathleen
公开号:US20050261372A1
公开(公告)日:2005-11-24
The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C
1
-C
6
)alkyl, (C
3
-C
6
)alkenyl, 3-oxo(C
5
-C
6
)alkyl, 3-oxo(C
4
-C
6
)alken-2-yl, phenyl(C
1
-C
6
)alkyl, phenyl(C
2
-C
6
)alkenyl, gem-diphenyl(C
1
-C
6
)alkyl, gem-diphenyl(C
2
-C
6
)alkenyl, (C
1
-C
6
)alcanoyl, optionally N-substituted alanyl, optionally N,N′-disubstituted lysinoyl, phenyl(C
1
-C
6
)alkylydene or gem-diphenyl(C
1
-C
6
)alkylidene group, and of the pharmaceutically acceptable salts thereof, for preparation of medicaments intended for the treatment of CNS diseases due to reduced glycinergic transmission, particularly for the treatment of autism, schizophrenia and Alzheimer's disease, is described.
描述了使用R(+)-2-氨基-3-羟基丙酸衍生物的用途,氮被(C1-C6)烷基,(C3-C6)烯基,3-氧代(C5-C6)烷基,3-氧代(C4-C6)烯基,苯基(C1-C6)烷基,苯基(C2-C6)烯基,双苯基(C1-C6)烷基,双苯基(C2-C6)烯基,(C1-C6)醇酰基,可选择地N-取代丙氨酰基,可选择地N,N′-二取代赖氨酰基,苯基(C1-C6)烷基亚烯基或双苯基(C1-C6)烷基亚烯基团及其药学上可接受的盐,用于制备用于治疗由于甘氨酸递质传递减少而引起的中枢神经系统疾病的药物,特别是用于治疗自闭症、精神分裂症和阿尔茨海默病。